A single-arm open-label clinical trial of autologous epidermal cell transplantation for stable vitiligo: A 30-month follow-up

Orouji, Z; Bajouri, Amir; Ghasemi, Mahshid; Mohammadi, Parvaneh; Fallah, Nasrin; Shahbazi, Afsaneh; Rezvani, Mohammad Ebrahim; Vaezirad, Fatemeh; Z, Khalajasadi; Alizadeh, Ahad; Taghiabadi, Ehsan; Dashtbozorgi, Sara; Aghdami, Raheleh; Hosseini, Seyedeh Esmat; Bahahrvand, Hossein; Shafieyan, Saeed; Aghdami, Nasser

doi:10.1016/j.jdermsci.2017.10.007

Cited by 17 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intralesional injection of NCES was also attempted in a recent study involving a large number of cases (300) where >50% repigmentation was obtained in 32.2% of treated patches (1,060) 9 months after therapy. 54 …”

Section: Introductionmentioning

confidence: 99%

Autologous non-cultured melanocyte–keratinocyte transplantation in the treatment of vitiligo: patient selection and perspectives

Bassiouny

Esmat

2018

CCID

View full text Add to dashboard Cite

Autologous non-cultured melanocyte–keratinocyte transplantation procedure (MKTP) is one of the simplest cellular grafting techniques. Various modifications were done over the years to make the technique easier and more economical which led to its great popularity among dermatologists. Proper patient selection and good technical skills are essential for achieving success with this technique. In this review, different patient-related and procedure-related factors that affect the outcome are discussed. This review may guide dermatologists to select suitable candidates, and explains what to expect in each case and indicates different techniques which can be used. The expected complications and stability of acquired pigmentation, which are an essential part of the pretreatment patient counseling, are also discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

Autologous non-cultured melanocyte–keratinocyte transplantation in the treatment of vitiligo: patient selection and perspectives

Bassiouny

Esmat

2018

CCID

View full text Add to dashboard Cite

show abstract

“…The donor tissue was immediately transferred to 10 mL of Hanks Black Solution Solvent (HBSS) buffer (Sigma Chemicals, St. Louis, Mo, USA). The isolation of epidermal cells was performed as previously described (1,11). Cell viability was checked by the dye trypan blue and cells were simultaneously counted using a Neuberger's chamber under a light microscope; this would also identify whether the cells were viable as the dead ones stained blue.…”

Section: Cell Suspension Preparationmentioning

confidence: 99%

“…Vitiligo is a common acquired disorder of pigmentation characterized by the development of well-defined white patches on the skin. Biopsies of skin layers reveal the loss of epidermal melanocytes (1,2). Melanocytes are specialized pigmented cells responsible for producing skin pigments.…”

Section: Introductionmentioning

confidence: 99%

One-Year Follow-Up of Vitiligo Patients Treated with Autologous Non-Cultured Melanocytes

Shahbazi

Naseh²,

Habibi

et al. 2020

Iran Red Crescent Med J

Self Cite

View full text Add to dashboard Cite

Background: Vitiligo is a long-term multifactorial polygenic disorder, characterized by the patchy loss of pigments in the skin. Several treatments including therapeutic creams and oral drugs are used to treat vitiligo with varying degrees of success. Some medical treatments can reduce the severity of the disease, but it is difficult to cure the disorder. Autologous non-cultured melanocyte transplantation is an effective method of vitiligo treatment. The utilization of appropriate cell suspension is a safe and efficient strategy to cure such hypopigmentation disorder. Objectives: The aim of this study was to follow up patients suffering from generalized and stable vitiligo who were treated with transplanted cells. Patients with patches in four different parts (forehead, eyelids, trunks, and hands) were selected because skin thickness varied among different body parts. We compared melanin repigmentation in these areas. Methods: We recruited 39 patients with generalized and stable vitiligo who had patches on their forehead, eyelids, trunks, and hands. Partial grafts were taken from the gluteal regions of all patients. Epidermal cells including non-cultured melanocyte and keratinocyte suspensions were enzymatically isolated and found to be of > 98% viability. Cells were injected intraepidemally. After a 12-month follow-up, repigmentation was observed. Results: The mean repigmentation score continued to improve up to 12 months post-transplantation. The obtained results confirmed that the cellular suspension that consisted of a mixture of epidermal cells improved to restore the normal color of the repigmentation rate. The number of received cells per cm 2 positively influenced the repigmentation score. Patches located on the face, neck, and trunk areas showed significantly higher responses to treatment. The pigmentation score was classified as "poor" (1% -25%), "moderate" (26% -50%), and "good" (51% -75%). This study is a research and clinical study with a brief report registered with the Ethics Committee of Avicenna Research Institute, clinical trials (letter number: 93/22/01/89), Tehran, Iran. Conclusions: The application of autologous non-cultured melanocyte-keratinocyte cell suspension could restore the patchy skin color to a near-normal level and the majority of the patients were satisfied with the results.

show abstract

“…Most skin substitutes are acellular; however, in the last few years increasing attention has been paid to the development of cellular substitutes mainly manufactured using two types of cells: fibroblasts and keratinocytes. [4][5][6] Moreover, recent researches also include new cell types such as melanocytes, 7 mesenchymal stem cells (MSCs), 8 epidermal stem cells, 9 hair follicle stem cells 10 and even cell-based products such as platelet-rich-plasma (PRP). [11][12][13] New approaches for skin TE are focused on combining novel natural or synthetic materials and living cells in several biomedical and pharmaceutical applications.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic strategies for skin regeneration based on biomedical substitutes

Chocarro‐Wrona

López‐Ruiz

Perán

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Regenerative medicine and tissue engineering (TE) have experienced significant advances in the development of in vitro engineered skin substitutes, either for replacement of lost tissue in skin injuries or for the generation of in vitro human skin models to research. However, currently available skin substitutes present different limitations such as expensive costs, abnormal skin microstructure and engraftment failure. Given these limitations, new technologies, based on advanced therapies and regenerative medicine, have been applied to develop skin substitutes with several pharmaceutical applications that include injectable cell suspensions, cell‐spray devices, sheets or 3Dscaffolds for skin tissue regeneration and others. Clinical practice for skin injuries has evolved to incorporate these innovative applications to facilitate wound healing, improve the barrier function of the skin, prevent infections, manage pain and even to ameliorate long‐term aesthetic results. In this article, we review current commercially available skin substitutes for clinical use, as well as the latest advances in biomedical and pharmaceutical applications used to design advanced therapies and medical products for wound healing and skin regeneration. We highlight the current progress in clinical trials for wound healing as well as the new technologies that are being developed and hold the potential to generate skin substitutes such as 3D bioprinting‐based strategies.

show abstract

A single-arm open-label clinical trial of autologous epidermal cell transplantation for stable vitiligo: A 30-month follow-up

Cited by 17 publications

References 32 publications

Autologous non-cultured melanocyte–keratinocyte transplantation in the treatment of vitiligo: patient selection and perspectives

Autologous non-cultured melanocyte–keratinocyte transplantation in the treatment of vitiligo: patient selection and perspectives

One-Year Follow-Up of Vitiligo Patients Treated with Autologous Non-Cultured Melanocytes

Therapeutic strategies for skin regeneration based on biomedical substitutes

Contact Info

Product

Resources

About

A single-arm open-label clinical trial of autologous epidermal cell transplantation for stable vitiligo: A 30-month follow-up

Cited by 17 publications

References 32 publications

Autologous non-cultured melanocyte&ndash;keratinocyte transplantation in the treatment of vitiligo: patient selection and perspectives

Autologous non-cultured melanocyte&ndash;keratinocyte transplantation in the treatment of vitiligo: patient selection and perspectives

One-Year Follow-Up of Vitiligo Patients Treated with Autologous Non-Cultured Melanocytes

Therapeutic strategies for skin regeneration based on biomedical substitutes

Contact Info

Product

Resources

About

Autologous non-cultured melanocyte–keratinocyte transplantation in the treatment of vitiligo: patient selection and perspectives

Autologous non-cultured melanocyte–keratinocyte transplantation in the treatment of vitiligo: patient selection and perspectives